IMM2902 for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Breast Cancer+2 MoreIMM2902 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug, IMM2902, to see if it is safe and effective in treating patients with advanced solid tumors that express the HER2 protein.

Eligible Conditions
  • Breast Cancer
  • Advanced Solid Tumors
  • Gastric Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: 48 Weeks

48 Weeks
Dose-Limiting Toxicity (DLT)
Number of patients with Adverse Events(AEs)
dose for expansion (RDE) of IMM2902
maximum tolerated dose (MTD) of IMM2902

Trial Safety

Trial Design

1 Treatment Group

IMM2902
1 of 1

Experimental Treatment

135 Total Participants · 1 Treatment Group

Primary Treatment: IMM2902 · No Placebo Group · Phase 1

IMM2902
Drug
Experimental Group · 1 Intervention: IMM2902 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 48 weeks

Who is running the clinical trial?

ImmuneOnco Biopharmaceuticals (Shanghai) Co., LtdLead Sponsor
3 Previous Clinical Trials
182 Total Patients Enrolled
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Lead Sponsor
4 Previous Clinical Trials
198 Total Patients Enrolled
Cheng Huang, MDStudy DirectorVP,Clinical Development
2 Previous Clinical Trials
166 Total Patients Enrolled
Frank Xiaodong GanStudy DirectorSVP, Clinical Development

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Weighs more than 30 kilograms.
You have HER2-low locally advanced or metastatic gastric/esophageal/GEJ cancer who have progression after 2 or more lines of systemic therapy.
You have HER2 IHC 3+ or HER2 IHC 2+/ISH-positive breast cancer.